This ones a heck of a specualive investment but it seems that the institutions are willing to stomp up the cash to back it in the long term.

Heres the latest news from Killik stocbrokers on the company..........

MEDICAL MARKETING Joint Venture

We recently highlighted Medical Marketing (MMG) as worthy of attention. The company, in which I have a personal share holding, has this morning announced the formation of a joint venture, Genvax, to develop a novel DNA vaccine platform technology.

Human trials have been underway since 2001 in areas such as Lymphoma and Myeloma but the technology has broad applications in cancer, viral and bacterial infections (hence the term platform). The technology works on boosting the immune system by teaching it to identify hard to recognise cancer proteins as foreign and destroy them. Early results from the 25 patient trial in lymphoma are encouraging and evaluation of the result is expected by March 2005. Successful results should mean big pharmaceutical groups will start to take financial and commercial interests around that time.

This looks to be the first of a series of announcements due from Medical Marketing as it has a range of predominantly cancer trials moving into the clinical stage. (news flow could push the price higher)

The stock has made good progress in recent sessions up to the mid-80p level where the company is valued at just under 40 million. ENDS.

Please DYOR

cheers GF.

Level 2 is free today on advfn if anyone is interested.

seawallwalker - it is free for a wekk here - see the free trial thread on the Bulletin Boards. Plus you can try our terminal system as well.

Ian

Thanks Ian.

I was not aware, been busy this week.

As I am today

regards

is the free level 2 available on this stock? or only the free demo on barclays?

MEDICAL MARKETING TO BE GRANTED 3RD US PATENT FOR RUTHENIUM CANCER DRUG

The above from Greystones thread.

Up and away surely...........

Here it is.

Medical Marketing Int'l Group PLC
10 June 2005


FOR IMMEDIATE RELEASE 10th JUNE 2005

MMI TO BE GRANTED
THIRD US PATENT FOR RUTHENIUM ANTI CANCER THERAPIES

Further strengthens patent position for Ruthenium in world's biggest market

Medical Marketing International Group plc ('MMI') (AIM: MMG), the Cambridge,
UK-based pharmaceutical company focussed on the development of therapies for
cancer and infectious diseases, announces that it has been formally notified of
allowance of claims for a third patent by the US Patent Office for its
ruthenium-based anti-cancer therapies, being developed by MMI's wholly-owned
cancer therapy subsidiary Oncosense.

This further patent significantly strengthens MMI's protection for its ruthenium
library containing thousands of compounds. Earlier patents already protect the
Company's lead anti-cancer compounds that will enter into clinical development
in 2005 for key tumour types.

Commenting on today's news, David Best, Chairman of MMI Group said: 'This new
notification of grant of our third ruthenium patent in the USA enhances our
commercial position in the world's largest cancer therapy market.

The scope of our three US patents, when added to the two European patents where
we have already received notification of grant, strengthens our negotiating
position with commercial partners. This when added to the laboratory safety and
efficacy data that we already have, creates a ruthenium class of cancer
therapies which have significant potential.'

Tha she goes...............

More patents on the way, I'm sure.

patents changes nothing on the fundamental side, the company still does not have a lot cash, they still needs fresh fund, whatever the patents

Patents will lead to grants and funds.

And leverage when negotiating with the big pharmas. As they say "Every little bit helps".

MS

David Best is quoted saying that the new patent "strengthens our negotiating position with commercial partners".
I think most here know they are already talking to big pharma.
Like to see Ru in P2 soon.

Your not the only one Pete...

From the other side.

A0469514 - 10 Jun'05 - 11:41 - 5845 of 5853


These presentations in Dublin and Jersey are not for issuing new news but are to make the investment community aware of the potential in MMI. On here, we know enough so that most of us realise that the potential is massive. My research in the company satisfies me that the ruthenium compounds are an almost certain future blockbuster which, alone, will transform the company and its share price. Today's announcement strengthens that likelihood. Furthermore the Genvax trials look very likely to me to have a high probability of success, in which case, there could be two or three massive products resulting from that programme too. If David Best can get that feeling across to the institutions then the share price is sure to respond. You do not tend to get immediate share price action resulting from these presentations but we should see some benefit over the next few days.

Xylos

Again from the other place. Xylos makes a lot of sence to me, a good poster.

A0469514 - 10 Jun'05 - 12:12 - 5848 of 5853


And as a further afterthought, whilst the general investment community may not be aware of what is happening, that most certainly will not be the case for the big pharmaceutical companies who, more than ever, are scouring the globe for just such opportunities that MMI appear to hold.

It is dangerous to make predictions on here, but I think that there is a strong likelihood, from hints that Mr Best has given out, that there will be a big deal with a top company BEFORE the ruthenium phase 2 trial starts. This will involve up front payments and further milestone payments, as each stage is successfully reached, followed by royalties when the products start to hit the market. Phase 2 trials are due to start in 2005 so we may not have long to wait. If that does happen, analysts will finally have a way to start valuing the company and I can only guess at what that might be.

Xylos

Sorry for the delay in reporting on the meeting that DB. had in Dublin. Unfortunatly my broker was unable to attend the meeting. Regards balt.

I think Xylos' comments are somewhat misleading. He states that from his research the Ru compounds are an almost certain blockbuster.
I don't think even David Best or Prof Peter Sadler would echo that sentiment and they are more in the know than anyone.
This is a drug that has yet to be tested on patients and with the recent high profile problems with the drugs Crestor and Iressa, it should be acknowledged that there is still a long, long way to go.

I do think Xylos' comments re: a deal may be closer than most think to be near the mark. All the extra tests and new patent all signal a change in direction from the AGM where Ru was to be in the clinic year end 2004.

Added a few more recently but as ever remain cautiuosly optimistic.

From the other side. Pete I hope this makes you feel a little more positive.

A0469514 - 12 Jun'05 - 09:13 - 5855 of 5858


Well, we will see. You have not convinced me yet guys.

There was another hint in David Best's presentation, if you remember. He said that they were taking the pre-clinical studies of the ruthenium compounds much further than was required by the FDA and other regulators. He said that they could easily have been in Phase 2 trials by now. The reason he gave for this was that they needed to attract big pharma and big pharma were crucially interested in safety so they were voluntarily doing extra studies.

The clear implication to me was that they were putting together a set of data which would be extremely attractive as a probable future blockbuster drug with a view to getting one of the major companies to fund all the clinical trials.

It all fits together as far as I am concerned but I may be wrong and in any case, it would depend on Mr Best's negotiating skills and whether he felt he could get the best deal now or a better deal by waiting.

I think that he might be very keen to clinch a deal now though. It would certainly dramatically improve the share price, get his company some big publicity and make negotiations on the other products that much easier.

Xylos

bolador - 12 Jun'05 - 13:06 - 5856 of 5858


Xylos, what you say is logical and I have no doubt that the directors
can pursue what ever route they feel is in the company's best interests,
however they should explain clearly what they are doing without the need
for you or anyone else to mind read or consider implications if they
have made a change in policy.

Given the opportunity I shall ask David Best if they plan to do a deal before
Phase 11 is completed at the forthcoming Jersey meeting on the 15th June.
In the meantime the mounting collection of patents is perhaps good reason
to believe something really important is being achieved here.



A0469514 - 12 Jun'05 - 15:29 - 5857 of 5858


Bolador, I am not sure that David Best has an obligation to spell out his strategy in detail to shareholders when he is trying to clinch a deal and I do not think that it would be fair to criticise him for keeping things close to his chest. If I was in his position, I do not think that I would wish to advertise the fact that I was in negotiations, otherwise the wider market would start building up expectations of a deal and, if it did not come, the share price could slide. I have seen this happen with other shares which I hold such as Proteome and Alizyme, for example.

I am sure that we will all be interested in David Best's reply to you but I suspect that he will not give much away. It will be far better for him to spring a successful deal onto the market and watch the share price take off. I think that he has the interests of shareholders in mind and we should trust him to make the best deal that he can when he judges that the time is right.

Nevertheless, my money is on a deal within weeks.

Xylos

All a bit quite so I got this from the other side. It might give the doubters hope.

A0469514 - 14 Jun'05 - 00:42 - 5859 of 5862


It's only a hunch guys, I do not have any inside information but I have done my research and I am predicting (I know I shouldn't do this) that the announcement for phase 2 trials for ruthenium cancer therapies (due in a matter of weeks) will also include details of a big pharma partnership. I am sticking my neck out a long way here, I know, but I will leave you to predict what that might do to the share price.

Xylos

bolador - 14 Jun'05 - 09:02 - 5860 of 5862


Death or glory, eh Xylos ?

johnwatson50 - 14 Jun'05 - 09:10 - 5861 of 5862


I have been following MMG for some time now like most on this board. I have recently topped up solely on the reasoning that news propells this share and news is due soon, ( how soon is anybodys guess ) and whether it is good news or not is again anybodys guess. However this company has a fantastic business model and they have some of the best people around working on the various projects. I therefore feel that the balance is in favour of good news not bad.

What other basis at this time do we have to make an invetment decision!!!



A0469514 - 14 Jun'05 - 09:32 - 5862 of 5862


Death or glory? Well if I am right, people will probably forget who predicted it. If I am wrong, well it doesn't matter too much. It will just mean that it will take a little longer to become a 10 bagger. I am pretty confident we will get to 15 a share in a year or two one way or another.

Xylos

Having reviewed comments here and reviewed the MMI business plan again, I think the views expressed here may be off the mark.
The business plan clearly states that a licensing deal will be sought once a drug has finished successful Phase 2 or is close to completing Phase 2.
There is only one MMI drug in that position at the moment.

Jersey presentation today.
Nothing new expected but might trigger a few buys.